25P DNA methylation biomarkers of clear cell renal carcinoma

Abstract

patients (6.84%), 8 men and 5 women in the age range 27 -81 years. Among the clinically most relevant fusions were identified ALK fusions (3 pts), ROS fusions (3 pts), and RET fusion (1 pt). 9 patients with detected EGFR mutations received targeted treatment. In additional 5 patients the targeted therapeutics are planned. Targeted treatment was administrated to 5 patients with detected gene fusions, mainly ALK and ROS1, in one patient the targeted therapy is planned. Conclusions:The introduction of sequencing techniques brings the relevant information about actionable molecular alterations into the multimodal management of lung cancer patients. As we showed in our study, the use of targeted NGS panel is a reliable approach for NSCLC molecular profiling and can be applied in personalized treatment decision making in routine clinical care of lung cancer patients.Legal entity responsible for the study: The authors.

Biomarkers in renal cell carcinoma and their targeted therapies: a review

“…In the tissue samples, detrimental clinicopathologic specifications are notably linked to hypermethylation of ZNF677 and PCDH8 . In another comparative study, Kubiliutė et al [ 31 ] performed DNA methylation analysis of potential biomarkers in urine samples from RCC patients and asymptomatic controls through two-colour Human DNA Methylation 1 × 244K Microarrays and methylation sensitive PCR. The comparison of RCC (specifically ccRCC) and NRT samples revealed significantly higher methylation at the regulatory regions of all investigated biomarkers in ccRCC tissues as compared to NRT tissues.…”